3-fluoro-3-methylpiperidine hydrochloride | 1820650-42-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-fluoro-3-methylpiperidine hydrochloride
• 英文别名: 3-fluoro-3-methylpiperidine;hydrochloride
• CAS: 1820650-42-7
• 化学式: C₆H₁₂FN*ClH
• 分子量: 153.627
• InChiKey: KFGJOBBINYSFLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.52
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(3-(3-((4-methyl-4H-1,2,4-triazol-3-yl)methyl)oxetan-3-yl)phenyl)-3-oxo-7-(trifluoromethyl)isoindoline-5-carbaldehyde 、 3-fluoro-3-methylpiperidine hydrochloride 在 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以9.6 mg的产率得到(R)-6-((3-fluoro-3-methylpiperidin-1-yl)methyl)-2-(3-(3-((4-methyl-4H-1,2,4-triazol-3-yl)methyl)oxetan-3-yl)phenyl)-4-(trifluoromethyl) isoindolin-1-one
  参考文献：
  名称：

  WO2020210508A5

  摘要：

  公开号：

  WO2020210508A5

文献信息

• 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS
  申请人：Nurix Therapeutics, Inc.

  公开号：EP3953346A1

  公开（公告）日：2022-02-16
• [EN] 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS<br/>[FR] COMPOSÉS DE PIPÉRIDINE SUBSTITUÉS EN POSITION 3 POUR L'INHIBITION DE CBL-B, ET UTILISATION D'UN INHIBITEUR DE CBL-B EN COMBINAISON AVEC UN VACCIN CONTRE LE CANCER ET/OU UN VIRUS ONCOLYTIQUE
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2020210508A1

  公开（公告）日：2020-10-15

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.